Heparan sulfate proteoglycan–Tumor necrosis factor-alpha signaling complex (HSPG–TNF-α complex) (HSPG–TNF-α complex)

The Heparan sulfate proteoglycan (HSPG)–Tumor necrosis factor-alpha (TNF-α) signaling complex is a regulatory assembly that modulates the bioavailability and signaling potency of the cytokine TNF-α. HSPGs, such as syndecans and glypicans, are cell-surface and extracellular matrix glycoproteins that bind TNF-α via their negatively charged heparan sulfate glycosaminoglycan chains [1] (Zhang et al., 2005, J Biol Chem). This interaction serves as a co-receptor mechanism, concentrating TNF-α at the cell surface and facilitating its presentation to the high-affinity signaling receptors TNFR1 and TNFR2 [2] (Parish, 2006, Nat Rev Immunol). Additionally, the complex protects TNF-α from proteolytic degradation and helps establish cytokine gradients necessary for leukocyte recruitment during inflammation [3] (Jalkanen et al., 1987, J Cell Biol). In pathological conditions like chronic inflammation, rheumatoid arthritis, and cancer, the dysregulation of this complex can lead to persistent and localized TNF-α signaling, contributing to tissue damage and tumor progression. Therapeutic strategies targeting this complex involve heparin mimetics or competitive inhibitors that disrupt the binding between HSPG chains and the heparin-binding domain of TNF-α, thereby dampening the downstream inflammatory cascade [4] (Ferro et al., 2004, Drug Dev Res). By modulating the local concentration of TNF-α rather than blocking its receptors globally, these therapies aim to achieve a more localized and controlled anti-inflammatory effect.

Other names

HSPG-TNF complexSyndecan-TNF-alpha complexHeparan sulfate-TNF-alpha interactionTNF-alpha-HSPG assemblyMembrane proteoglycan-TNF signaling unit

Disruption of the electrostatic interaction between the negatively charged heparan sulfate glycosaminoglycan chains of the proteoglycan and the basic heparin-binding domain of TNF-alpha, thereby preventing cytokine sequestration, stabilization, and presentation to signaling receptors TNFR1 and TNFR2 [1, 4].